[1]沈孟杰.注射用头孢哌酮钠舒巴坦钠临床应用效果及 不良反应发生情况研究[J].医学信息,2018,31(12):131-133.[doi:10.3969/j.issn.1006-1959.2018.12.040]
　SHEN Meng-jie.Clinical Application and Adverse Reactions of Cefoperazone Sodium and Sulbactam Sodium for Injection[J].Journal of Medical Information,2018,31(12):131-133.[doi:10.3969/j.issn.1006-1959.2018.12.040]
点击复制

注射用头孢哌酮钠舒巴坦钠临床应用效果及 不良反应发生情况研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年12期
页码:
131-133
栏目:
药物与临床
出版日期:
2018-06-15

文章信息/Info

Title:
Clinical Application and Adverse Reactions of Cefoperazone Sodium and Sulbactam Sodium for Injection
文章编号:
1006-1959（2018）12-0131-03
作者:
沈孟杰
天津市第三中心医院分院药剂科，天津 300250
Author(s):
SHEN Meng-jie
Department of Pharmacy,Tianjin Third Central Hospital Branch,Tianjin 300250,China
关键词:
头孢哌酮钠舒巴坦钠; 重症感染; 不良反应
Keywords:
Key words：Cefoperazone sodium sulbactam sodium; Severe infection; Adverse reactions
分类号:
R978.1
DOI:
10.3969/j.issn.1006-1959.2018.12.040
文献标志码:
A
摘要:
目的 从细菌学、不良反应评价注射用头孢哌酮钠舒巴坦钠应用价值，分析疗效影响因素，为医院遴选抗菌药物、合理用药提供参考。方法 2017年1月~12月我院共使用注射用头孢哌哃钠舒巴坦钠治疗重症感染患者254例，将痊愈对象纳入痊愈组，其余纳入对照组，收集资料，进行因素分析。描述性分析不良反应发生情况。结果 感染控制率94.49%（240/254），微生物清除率87.01%（221/254），未见细菌交替、再感染情况。痊愈率49.21%（125/254）、有效率47.24%（120/254）、无效率3.54%（9/254）。多因素Logistic回归分析：热程[OR=1.016，95%CI(0.985~1.106]、PLT[OR=0.924，95%CI(0.542~0.947)]、抗生素耐药[OR=13.426，95%CI(1.566~44.115)]、混合感染[OR=1.126，95%CI(1.247~1.547]、精神萎靡不振[OR=1.257，95%CI(1.468~3.918)]、有并发症[OR=1.225，95%CI(1.114~2.359)]成为独立影响因素（P＜0.05）。未见注射用头孢哌酮钠舒巴坦有关严重不良反应，出现1例菌群失调。结论 注射用头孢哌酮钠舒巴坦钠不良反应发生率低，单中心应用于重症感染疗效肯定，但疗效容易受到多种因素影响，需要加强耐药性、病原学监测，提高经验性用药水平。
Abstract:
Abstract：Objective To evaluate the value of cefoperazone sodium and sulbactam sodium for injection from bacteriological and adverse reactions,analyze the influencing factors,and provide reference for hospital selection of antimicrobial drugs and rational drug use.Methods A total of 254 patients with severe infections were treated with cefoperazone sodium and sulbactam sodium for injection from January to December 2017.The recovery targets were included in the recovery group and the rest were included in the control group.Data were collected and factor analysis was performed.Descriptive analysis of the occurrence of adverse reactions.Results The infection control rate was 94.49%(240/254)and the microbial clearance rate was 87.01%(221/254).There was no bacterial alternation and reinfection.The cure rate was 49.21%(125/254),the effective rate was 47.24%(120/254),and the inefficiency was 3.54%(9/254). Multivariate logistic regression analysis: heat history[OR=1.016,95%CI(0.985~1.106],PLT[OR=0.924,95% CI(0.542~0.947)],antibiotic resistance[OR=13.426,95% CI(1.566~44.115)],mixed infection[OR=1.126,95%CI(1.247~1.547],lack of spirit[OR=1.257,95%CI(1.468~3.918)],with complications[OR=1.225,95%CI(1.114~2.359)became an independent influencing factor(P<0.05).There was no serious adverse reaction related to cefoperazone sodium sulbactam for injection,and 1 case of dysbacteriosis occurred.Conclusion The incidence of adverse reactions of cefoperazone sodium and sulbactam sodium for injection is low.Single-center application of severe infection is affirmative,but the efficacy is easily affected by many factors.It is necessary to strengthen drug resistance,pathogen monitoring,and improve the level of empirical drug use.

参考文献/References:

[1]《抗菌药物临床应用试验技术指导原则》课题组.抗菌药物临床应用试验技术指导原则(第3稿)[Z].北京,2007.
[2]茅国峰,徐儿.哌拉西林/他唑巴坦与头孢哌酮/舒巴坦治疗细菌性感染疗效的Meta分析[J].中华实验和临床感染病杂志,2016,10(3):269-273.
[3]左蕾,杨晓秋,刘丹彦,等.头孢哌酮钠/舒巴坦钠治疗临床重症感染的meta评价[J].中国老年学杂志,2017,37(7):1715-1717.
[4]许敬菊,程慎令,丛晓荣.头孢哌酮/舒巴坦治疗下呼吸道感染的疗效及耐药趋势分析[J].中华医院感染学杂志,2015,25(1):91-95.
[5]褚云卓,田素飞,年华,等.2011年度全国细菌耐药监测报告:65岁以上老年患者细菌耐药监测[J].中国临床药理学杂志,2014,2(30):89-95.

相似文献/References:

[1]柳 梅.头孢哌酮钠舒巴坦钠治疗糖尿病并发尿路感染的 临床效果观察[J].医学信息,2018,31(07):139.[doi:10.3969/j.issn.1006-1959.2018.07.047]
　LIU Mei.Clinical Efficacy of Cefoperazone Sodium and Sulbactam Sodium in Treatment of Diabetes Complicated with Urinary Tract Infection[J].Journal of Medical Information,2018,31(12):139.[doi:10.3969/j.issn.1006-1959.2018.07.047]
[2]张曼丽.重症感染患者血磷水平与免疫指标对预后影响[J].医学信息,2018,31(20):88.[doi:10.3969/j.issn.1006-1959.2018.20.025]
　ZHANG Man-li.Effect of Blood Phosphorus Level and Immune Index on Prognosis in Patients with Severe Infection[J].Journal of Medical Information,2018,31(12):88.[doi:10.3969/j.issn.1006-1959.2018.20.025]
[3]隋文峰,马海英,潘 雪.乌司他丁联合头孢哌酮钠舒巴坦钠注射剂治疗重症肺部感染的疗效[J].医学信息,2020,33(19):143.[doi:10.3969/j.issn.1006-1959.2020.19.044]
　SUI Wen-feng,MA Hai-ying,PAN Xue.The Efficacy of Ulinastatin Combined with Cefoperazone Sodium and Sulbactam Sodium Injection in the Treatment of Severe Pulmonary Infection[J].Journal of Medical Information,2020,33(12):143.[doi:10.3969/j.issn.1006-1959.2020.19.044]
[4]魏长斌.头孢哌酮钠舒巴坦钠对糖尿病合并尿路感染的疗效及安全性分析[J].医学信息,2021,34(14):151.[doi:10.3969/j.issn.1006-1959.2021.14.042]
　WEI Chang-bin.Analysis of the Efficacy and Safety of Cefoperazone Sodium and Sulbactam Sodium on Diabetes Complicated with Urinary Tract Infection[J].Journal of Medical Information,2021,34(12):151.[doi:10.3969/j.issn.1006-1959.2021.14.042]

更新日期/Last Update: 2018-06-15